Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

SHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

Inside the study for a remedy to fight Congo’s deadliest Ebola outbreak

More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo, in what experts have described as a critical step to try to fight the ...
Yahoo Finance

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces ...
Medical News Today

New Ebola treatment trial offers hope: 3 questions answered

Clinical trial for targeted new Ebola treatment begins enrollment in the Democratic Republic of the Congo. Image credit: PixelCatchers/Getty Images On July 2, 2026, the World Health Organization (WHO) ...

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over ...

SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...
WHO | Regional Office for Africa

From illness to hope: mental health at the heart of the Ebola response

When I was told I had Ebola, I already felt like a dead man,” recalls Jean Vianney, 44, who has now recovered from the ...

An Ebola Treatment Center Was Burned Down As The Death Toll In Congo Passes 4,000

Congo announced an outbreak on May 15, caused by the rare Bundibugyo virus, which has no known treatment or vaccine.